Pathways to Improved Outcomes: Diagnosis, Monitoring, and Individualized Treatment of Progressive Fibrosing ILD

Steering Committee
Kevin R. Flaherty, MD, MS, FCCP (Chair)
Professor of Internal Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan
Ann Arbor, MI

Erica L. Herzog, MD, PhD
Department of Internal Medicine
Section of Pulmonary, Critical Care, and Sleep Medicine
Director, Interstitial Lung Disease Center of Excellence
Yale School of Medicine
New Haven, CT

Lisa H. Lancaster, MD
Associate Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Medical Director, Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Contributing Faculty
Edwin F. Donnelly, MD, PhD
Associate Professor of Radiology and Radiological Sciences
Vanderbilt University Medical Center
Associate Professor of Biomedical Engineering
Vanderbilt University
Nashville, TN

Wendi R. Mason, MSN, RN, ACNP-BC
Assistant in Medicine, Nurse Practitioner
Director, ILD Research Unit
Vanderbilt University Medical Center
Nashville, TN

Patient Faculty
Betty McDaniel
Bowling Green, KY

This activity is provided by Paradigm Medical Communications, LLC.  

Target Audience
This activity has been designed to address the educational needs of pulmonologists, radiologists, and pathologists. It may also benefit rheumatologists, primary care physicians, respiratory therapists, PAs, nurse practitioners (NPs), nurses, pharmacists, fellows, residents, and other allied healthcare providers (HCPs) who care for patients with interstitial lung disease (ILD).

Statement of Need
ILD is progressive and severely debilitating. Clinicians need to understand the key diagnostic features of ILD and be able to distinguish among different types, particularly those associated with a progressive lung phenotype, including inflammatory connective-tissue diseases (eg, rheumatoid arthritis) and chronic hypersensitivity pneumonitis, as well as unclassified ILD, which can lead to increased morbidity and mortality. Lack of knowledge and understanding of test parameters for patients at risk of progressive fibrosing ILD (PF-ILD), as well as deficits in understanding of disease management, available recommendations, and recent clinical research, are significant barriers to improving outcomes and quality of life for patients with ILD with a progressive lung phenotype. The goal of this activity is to improve recognition and diagnosis of PF-ILD, and to improve management of these patients through integration of traditional and newer therapy options into routine practice.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:
• Correctly identify patients with a phenotype of PF-ILD 
• Describe appropriate monitoring and subsequent impact on morbidity and mortality of these assessments for patients with PF-ILD
• Assess evidence from recent and ongoing clinical trials for its impact on the management of PF-ILD

• Introduction to PF-ILD
• Identification, Testing, and Monitoring Patients at Risk for PF-ILD
• Differential Diagnosis and Classification of PF-ILD
• VIRTUAL VIDEO CONSULT: The Multidisciplinary Discussion (MDD) Case Study
• Emerging Research and Approaches to the Management of PF-ILD
• VIRTUAL VIDEO CONSULT: The Patient Discussion
• Q&A and Discussion
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Conflicts of Interest
In accordance with ACCME requirements on disclosure, information about relationships with commercial interests (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity.
To register for this complimentary symposium, please click Continue below or call toll-free: (877) 252-5100, ext. 1.